StemRIM Begins Phase 2 Trial for Cardiomyopathy Treatment

StemRIM Inc. (JP:4599) has released an update.

StemRIM Inc. has commenced a Phase 2 clinical trial for its regenerative medicine product, Redasemtide, targeting ischemic cardiomyopathy at Osaka University Hospital. This trial aims to evaluate the efficacy and safety of the treatment in patients who have undergone coronary artery bypass grafting, with results expected to be monitored 52 weeks post-treatment. Despite this development, it is not anticipated to impact the company’s financial results for the current fiscal year.

For further insights into JP:4599 stock, check out TipRanks’ Stock Analysis page.